You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

aloxi Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Aloxi, and when can generic versions of Aloxi launch?

Aloxi is a drug marketed by Helsinn Hlthcare and is included in two NDAs. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in forty countries.

The generic ingredient in ALOXI is palonosetron hydrochloride. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the palonosetron hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for aloxi?
  • What are the global sales for aloxi?
  • What is Average Wholesale Price for aloxi?
Drug patent expirations by year for aloxi
Drug Prices for aloxi

See drug prices for aloxi

Paragraph IV (Patent) Challenges for ALOXI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ALOXI Injection palonosetron hydrochloride 0.05 mg/mL, 1.5 mL and 5 mL vials 021372 3 2011-05-27

US Patents and Regulatory Information for aloxi

aloxi is protected by seven US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare ALOXI palonosetron hydrochloride CAPSULE;ORAL 022233-001 Aug 22, 2008 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 DISCN Yes No 9,125,905*PED ⤷  Subscribe Y ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-002 Feb 29, 2008 DISCN Yes No 9,173,942*PED ⤷  Subscribe Y ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-002 Feb 29, 2008 DISCN Yes No 7,960,424*PED ⤷  Subscribe Y ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 DISCN Yes No 7,960,424*PED ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for aloxi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 9,125,905*PED ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 7,960,424*PED ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-002 Feb 29, 2008 9,173,942*PED ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 8,518,981*PED ⤷  Subscribe
Helsinn Hlthcare ALOXI palonosetron hydrochloride INJECTABLE;INTRAVENOUS 021372-001 Jul 25, 2003 9,457,021*PED ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for aloxi

See the table below for patents covering aloxi around the world.

Country Patent Number Title Estimated Expiration
Spain 2075121 ⤷  Subscribe
Tunisia SN05180 LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON ⤷  Subscribe
Mexico PA05008028 FORMULACIONES FARMACEUTICAS LIQUIDAS DE PALONOSETRON. (LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON.) ⤷  Subscribe
Eurasian Patent Organization 200501203 ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ПАЛОНОСЕТРОНА ⤷  Subscribe
China 1758911 Liquid pharmaceutical formulations of palonosetron ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for aloxi

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0430190 SPC/GB05/032 United Kingdom ⤷  Subscribe PRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322
0430190 18/2005 Austria ⤷  Subscribe PRODUCT NAME: PALONOSETRON, DESSEN SALZE UND STEREOISOMERE; REGISTRATION NO/DATE: EU/1/04/306/001 20050322
0430190 CA 2005 00023 Denmark ⤷  Subscribe
1035115 92745 Luxembourg ⤷  Subscribe PRODUCT NAME: NETUPITANT/PALONOSETRON ET LEURS DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (AKYNZEO); FIRST REGISTRATION: 20150527
2785706 2020C/516 Belgium ⤷  Subscribe PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Aloxi Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ALOXI

Introduction

ALOXI, known generically as palonosetron hydrochloride, is a significant player in the Chemotherapy-Induced Nausea and Vomiting (CINV) drugs market. Here, we delve into the market dynamics and financial trajectory of ALOXI, highlighting its position, growth prospects, and key factors influencing its market performance.

Market Size and Growth

The global CINV existing and pipeline drugs market, within which ALOXI operates, was valued at USD 1.62 billion in 2023 and is expected to grow at a CAGR of 4.9% from 2024 to 2030, reaching nearly USD 2.27 billion by 2030[1][4].

Segmentation and Market Share

ALOXI is categorized under the second-generation serotonin receptor blockers, a segment that is expected to hold a lucrative share of the global CINV market. The drug is particularly noted for its efficacy in preventing acute and delayed nausea and vomiting associated with chemotherapy[1][5].

Regional Performance

North America holds the largest share of the global CINV market, and ALOXI, being approved and widely used in this region, benefits significantly from this dominance. Europe is the second-largest market, although the launch of CINV pipeline drugs, including ALOXI, may be delayed compared to North America[1].

End-Use Segmentation

The market is segmented by end-use into hospitals, specialty clinics, diagnostic centers, hospital pharmacies, and drugstores. Hospitals are the fastest-growing segment, driven by a rising patient population, which positively impacts the demand for ALOXI[1].

Competitive Landscape

ALOXI competes with other prominent CINV drugs such as Emend (aprepitant), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), and Rolapitant. Key players in the market include Helsinn, Heron Therapeutics, Merck, and others. ALOXI's unique selling point is its long-lasting efficacy and minimal side effects, which help it maintain a competitive edge[1][4].

Cost-Utility Analysis

A cost-utility analysis comparing oral palonosetron (ALOXI) with oral ondansetron revealed that while ALOXI is associated with higher costs, it offers minimal incremental quality-adjusted life years (QALYs). The incremental cost per QALY gained with ALOXI is significant, ranging from $9,175 to $39,581 depending on the treatment regimen and duration of use[2].

Clinical Efficacy

ALOXI has demonstrated strong clinical efficacy in preventing nausea and vomiting associated with chemotherapy. It is the first and only 5-HT3 receptor antagonist approved by the FDA for the prevention of acute and delayed nausea and vomiting in both moderately and highly emetogenic chemotherapy. Clinical trials have shown that ALOXI significantly reduces the severity of nausea and vomiting, with a complete response rate of 42.8% in the 0-24 hour period post-treatment[5].

Safety Profile

The safety profile of ALOXI is favorable, with common side effects including ECG QT prolongation, bradycardia, headache, and constipation. However, these side effects are generally mild and comparable to those of placebo in many cases[5].

Financial Performance

The financial performance of ALOXI is closely tied to the overall growth of the CINV market. With the market expected to grow at a CAGR of 4.9%, ALOXI is likely to see increased revenue. The drug's approval for additional indications, such as postoperative nausea and vomiting (PONV), further expands its market potential[1][5].

Key Takeaways

  • Market Growth: The CINV market, including ALOXI, is expected to grow at a CAGR of 4.9% from 2024 to 2030.
  • Competitive Edge: ALOXI's long-lasting efficacy and minimal side effects make it a preferred choice in the CINV market.
  • Regional Dominance: North America is the largest market for ALOXI, with Europe being the second-largest.
  • Clinical Efficacy: ALOXI has strong clinical efficacy in preventing nausea and vomiting associated with chemotherapy.
  • Cost-Utility: While ALOXI is more expensive, it offers minimal incremental QALYs compared to other treatments.

FAQs

  1. What is the expected growth rate of the CINV market, which includes ALOXI?

    • The CINV market is expected to grow at a CAGR of 4.9% from 2024 to 2030[1].
  2. Which region holds the largest share of the CINV market for ALOXI?

    • North America holds the largest share of the global CINV market[1].
  3. What are the common side effects associated with ALOXI?

    • Common side effects include ECG QT prolongation, bradycardia, headache, and constipation[5].
  4. How does ALOXI compare to other CINV drugs in terms of cost-utility?

    • ALOXI is associated with higher costs but offers minimal incremental QALYs compared to other treatments like ondansetron[2].
  5. What are the key indications for which ALOXI is approved?

    • ALOXI is approved for the prevention of acute and delayed nausea and vomiting associated with chemotherapy and postoperative nausea and vomiting (PONV)[5].

Sources

  1. Maximize Market Research: Global CINV Existing and Pipeline Drugs Market Report.
  2. CADTH: Final CDEC Recommendation – Palonosetron Capsule (Aloxi).
  3. Heron Therapeutics: Form 10-K for Heron Therapeutics INC DE filed 03/12/2024.
  4. Business Research Insights: CINV Existing and Pipeline Drugs Market Size, Forecast | 2032.
  5. Eisai Co., Ltd.: FDA APPROVES ALOXI® (PALONOSETRON HCL) INJECTION.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.